Daniel Rabczenko

Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové

Publication